Hepatitis C News

ATLANTA — An investigation identified a health care worker who was diverting injectable narcotics for personal use as the likely source of 13 hepatitis C virus infections in an ED in Washington state.

The FDA approved Mavyret to treat all six genotypes of hepatitis C in pediatric patients aged 12 years to 17 years, according to a press release from the organization.

VIENNA — In this exclusive video from the International Liver Congress 2019, Philippa Easterbrook, MD, senior scientist of the Global Hepatitis Program within the HIV Department at the WHO headquarters in Geneva, Switzerland, discusses the future of direct-acting antiviral access for children and adolescents with hepatitis C.

VIENNA — In this exclusive video from the International Liver Congress 2019, Olufunmilayo Lesi, FWACP, FMCP, from the University of Lagos in Nigeria, discusses the WHO’s goal for global elimination of viral hepatitis by the year 2030.

VIENNA — In this exclusive video from the International Liver Congress 2019, Heather Valerio, from the Kirby Institute at the University of New South Wales in Australia, provides an overview of the Enhancing Treatment of Hepatitis C in Opioid Substitution Settings Engage study of hepatitis C outcomes among people who inject drugs.

More than 55% of people who inject drugs, or PWID, in eight United States cities were found to have been infected with hepatitis C virus, including almost half of young PWID, according to study findings that also showed infection was associated with risky injection practices.

VIENNA — In this exclusive video from the International Liver Congress 2019, Marc Bulterys, MD, PhD, team leader of the Global Hepatitis Program at the World Health Organization in Geneva, Switzerland, discusses the prevention, care and treatment of hepatitis B and hepatitis C among children and adolescents.

VIENNA — In the face of the remaining gaps in the hepatitis C care cascade, timely screening, monitoring and linkage to care by general practitioners coupled with early treatment by specialists could effectively reduce the hepatic and extrahepatic burden of the virus, according to a real-world analysis presented at the International Liver Congress 2019.

VIENNA — Patients with hepatitis C genotype 3 and compensated cirrhosis had higher rates of sustained virologic response after treatment with Epclusa and ribavirin than with Epclusa alone or combined Sovaldi and Daklinza with ribavirin.

VIENNA — Use of adenovirus derived from chimpanzees showed increased activity and sustainability of T cell activation in an early study of a vaccine for hepatitis C virus, according to new data presented during the International Liver Congress.